Self-monitoring of blood glucose (SMBG) provided no clinical benefit to patients with type 2 diabetes not treated with insulin according to a recent trial published in JAMA Internal Medicine. Clinicians should consider each patient’s clinical situation before recommending home glucose monitoring, the authors advised.
The 450 participants were randomized to 3 groups: no SMBG, once-daily SMBG, and once-daily SMBG with enhanced feedback messages delivered through their blood glucose meters. The participants’ average age was 61 years, they had had diabetes for an average of 8 years, and they had hemoglobin A1c levels higher than 6.5% but lower than 9.5%. Seventy-five percent already performed SMBG.
Slomski A. Home Monitoring Fails to Improve Glycemic Control. JAMA. 2017;318(8):690. doi:10.1001/jama.2017.10991
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: